Analysis of RASSF1A promoter hypermethylation in serum DNA of non-small cell lung cancer patients

Zheng-hong YU,Yui-cai WANG,Long-bang CHEN,Yong SONG,Chang LIU,Xin-yi XIA,Qing LIN,Chi-yuan MA

DOI: https://doi.org/10.3321/j.issn:0253-3766.2008.04.011

2008-01-01

Abstract:Objective To detect the hypermethylation status of RASSF1 A promoter in selMm DNA of non-small cell lung cancer(NSCLC)patient and evaluate its correlation with clinicopathological parameters.Methods Serum DNA was extracted from the peripheral blood of 75 NSCLC patients and another 35 patients with benign pulmonary disease and 15 healthy donors.The methylation status of RASSF1 A promoter was determined using mthylation-specific PCR(MSP),and the correlation of methylation profiles with clinicopathological parameters was statistically analyzed. Results Aberrant methylation of RASSF1 A was detected in 23 of 75(30.7%)cancer patients.but in none of patients with benign pulmonary disease or in healthy donors(P＜0.001).RASSF1 A hypermethylation status Was found to be correlated with late stage and poor differentiation(P＜0.05),but not with gender,age or histopathology in NSCLC patients.Conclusion Hypermethylated RASSF1 A promoter is frequently found in the serum DNA of non-small cell lung cancer patient,and RASSF1 A may become a promising novel biomarker for diagnosis and prognosis prediction in lung cancer.